Luye Pharma Announces 2020 Annual Results

• LY-CovMab, an innovative antibody for the treatment of new coronary pneumonia, is in the final stage of Phase I clinical trials in China;
• Boyouno® (bevacizumab injection) is in the application stage in China and is expected to be approved for marketing in mid-2021;
• Prolia® biosimilar (LY06006) completed the final administration of phase III clinical trials for all subjects in China, and is expected to submit a marketing application by the end of 2021; it will be approved for clinical entry in Europe and the United States;
• Xgeva® biosimilar (LY01011) entered phase III clinical trials in China; it was approved to enter clinical trials in Europe and America;
• Eylea® biosimilar (LY09004) completed the first case of phase III clinical administration in China;

• Completion of the acquisition of Boan Biological;
• Obtained a strategic investment from Hillhouse Capital;

• The overseas introduction of the innovative anti-tumor drug Lurbinectedin has started clinical trials in China;
• Transdermal patch series products carry out extensive international authorization cooperation;
• Okvision was granted the right to promote LY09004 (Eylea® biosimilar) in China;

Focusing on the central nervous system and oncology, the company has carried out registration and clinical research on more than 10 innovative drugs and innovative preparations in the United States, Europe and Japan, many of which have entered the late-stage clinical and NDA stages
.

3.
Strengthen the international business system to help follow-up new drug sales

• Seroquel has established its own sales teams in the United Kingdom, Southeast Asia, the Middle East, and North Africa, and has reached external business cooperation in more than 10 countries and regions at the same time;
• Liss' Ming transdermal patch (multi-day patch) has reached a series of international development and commercialization authorizations, including Japan, Germany, Italy, Portugal, Greece and other markets;

Performance & Outlook-Fully prepare for the commercialization of new products

In 2020, the global rages of the new crown epidemic and the huge changes in the macro environment will put the pharmaceutical industry facing severe tests
.
Luye Pharma has adopted a number of reform measures to improve management and operational efficiency, realize the smooth operation of various businesses, and continue to increase R&D investment to maintain core competitiveness
.
During the reporting period, the company's sales revenue fell by 12.
9% year-on-year, and the overall performance maintained the industry average
.

In 2021, the company will further optimize management costs and efficiency, ensure the steady development of the business, and prepare for the imminent commercialization of multiple new products in the two core therapeutic areas of central nervous system and oncology
.

1.
Oncology

• Lipusu® successfully entered the national medical insurance through negotiations, and all its indications can be reimbursed by the national medical insurance.
  In the future, it will promote market sinking and cover more hospitals.
  The new product Boyouno® (bevacizumab injection) is launched Soon, it will also bring a strong growth point for the company's sales in the oncology field;

2.
Central nervous system

• Domestic market: With the listing of Rexinto® and Kingsmine®, it forms a more competitive product portfolio with existing Seroquel® products; the company has established a central nervous system academic promotion team with more than 100 people, covering the whole country More than 3,000 hospitals have vigorously expanded the market potential in this field
  .
  
• Overseas market: The launch of the innovative product Liss Ming transdermal patch (multi-day patch) will also become a new growth point
  .
  With the existing market resources and network of Seroquel® and transdermal patch products, it will provide more assistance for the commercialization of this product
  .
  

Looking forward to the future, the management of Luye Pharmaceutical Group stated: "In 2021, we will accelerate the implementation of the strategy of'innovation' and'internationalization' based on our existing accumulation and advantages, further utilize the advantages of independent innovation technology platform, and strengthen research and development.
Innovation capabilities, deepen the transformation and upgrading of cutting-edge technologies, accelerate the launch of new products and the construction of global commercialization capabilities, and enhance strategic advantages and sustainable growth
.
"